Literature DB >> 26918555

Glucose in prediabetic and diabetic range and outcome after stroke.

E Osei1, S Fonville2, A A M Zandbergen3, P J Koudstaal2, D W J Dippel2, H M den Hertog1.   

Abstract

OBJECTIVES: Newly diagnosed disturbed glucose metabolism is highly prevalent in patients with stroke. Limited data are available on their prognostic value on outcome after stroke. We aimed to assess the association of glucose in the prediabetic and diabetic range with unfavourable short-term outcome after stroke.
MATERIALS AND METHODS: We included 839 consecutive patients with ischemic stroke and 168 patients with intracerebral haemorrhage. In all nondiabetic patients, fasting glucose levels were determined on day 2-4. Prediabetic range was defined as fasting glucose of 5.6-6.9 mmol/L, diabetic range as ≥7.0 mmol/L, pre-existent diabetes as the use of anti-diabetic medication prior to admission. Outcome measures were poor functional outcome or death defined as modified Rankin Scale (mRS) score >2 and discharge not to home. The association of prediabetic range, diabetic range and pre-existent diabetes (versus normal glucose) with unfavourable outcome was expressed as odds ratios, estimated with multiple logistic regression, with adjustment for prognostic factors.
RESULTS: Compared with normal glucose, prediabetic range (aOR 1.8; 95%CI 1.1-2.8), diabetic range (aOR 2.5; 95%CI 1.3-4.9) and pre-existent diabetes (aOR 2.6; 95%CI 1.6-4.0) were associated with poor functional outcome or death. Patients in the prediabetic range (aOR 0.6; 95%CI 0.4-0.9), diabetic range (aOR 0.4; 95%CI 0.2-0.9) and pre-existent diabetes (aOR 0.6; 95%CI 0.4-0.9) were more likely not to be discharged to home.
CONCLUSIONS: Patients with glucose in the prediabetic and diabetic range have an increased risk of unfavourable short-term outcome after stroke. These findings illustrate the potential impact of early detection and treatment of these patients.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  diabetes; glucose; outcome; prediabetes; prognosis; stroke

Mesh:

Substances:

Year:  2016        PMID: 26918555     DOI: 10.1111/ane.12577

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  6 in total

1.  The Association between Impaired Glucose Regulation and Prognosis of Chinese Patients with Intracerebral Hemorrhage.

Authors:  Shichao Sun; Yuesong Pan; Xingquan Zhao; Liping Liu; Hao Li; Yan He; Li Guo; Yilong Wang; Yongjun Wang
Journal:  Sci Rep       Date:  2016-10-31       Impact factor: 4.379

Review 2.  Macrovascular Complications in Patients with Diabetes and Prediabetes.

Authors:  Dou Huang; Marwan Refaat; Kamel Mohammedi; Amin Jayyousi; Jassim Al Suwaidi; Charbel Abi Khalil
Journal:  Biomed Res Int       Date:  2017-11-07       Impact factor: 3.411

3.  LncRNA MALAT1 induced by hyperglycemia promotes microvascular endothelial cell apoptosis through activation of the miR-7641/TPR axis to exacerbate neurologic damage caused by cerebral small vessel disease.

Authors:  Fei Che; Yunfeng Han; Jinxia Fu; Nannan Wang; Yuehui Jia; Kun Wang; Jie Ge
Journal:  Ann Transl Med       Date:  2021-12

4.  Genetic and lifestyle predictors of ischemic stroke severity and outcome.

Authors:  Ivana Celap; Nora Nikolac Gabaj; Vida Demarin; Vanja Basic Kes; Ana-Maria Simundic
Journal:  Neurol Sci       Date:  2019-07-20       Impact factor: 3.307

5.  Prediabetes is associated with poor functional outcome in patients with intracerebral hemorrhage.

Authors:  Qiongzhang Wang; Guiqian Huang; Fei Chen; Pinglang Hu; Wenwei Ren; Xiaoqian Luan; ChengYe Zhou; Jincai He
Journal:  Brain Behav       Date:  2020-02-17       Impact factor: 2.708

6.  Fasting Blood-Glucose Level and Clinical Outcome in Anterior Circulation Ischemic Stroke of Different Age Groups After Endovascular Treatment.

Authors:  Lili Yuan; Yi Sun; Xianjun Huang; Xiangjun Xu; Junfeng Xu; Youqing Xu; Qian Yang; Yujuan Zhu; Zhiming Zhou
Journal:  Neuropsychiatr Dis Treat       Date:  2022-03-18       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.